Haiyan Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Haiyan Sun has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Anthony Sciscione
Christina Care Health System, Newark, DE
1 shared publication- Awathif Dhanya Mackeen
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Geisinger Health System, Danville, USA
1 shared publication - Chao Zhang
Department of Anesthesiology, The First Affiliated Hospital of Soochow University, 215006 Suzhou, Jiangsu, China
1 shared publication Christopher K. Huls
University of Arizona College of Medicine, Phoenix at Banner University Medical Center, Phoenix, AZ
1 shared publicationDanielle E. Durie
Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Lehigh Valley Health Network, Allentown, PA
1 shared publication- Fu-Hai Ji
Department of Anesthesiology, The First Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication
Latest Publications
- Open Access
- 25 September 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (9) , 43761
Argon Alleviates Bone Cancer Pain by Mitigating Neuronal Ferroptosis via the TLR2-COX-2 Pathway
Background: Bone cancer pain (BCP) related neuronal damage is associated with ferroptosis, a regulated cell death dependent on iron. The noble gas argon is known to have neuroprotective effects, reducing neuroinflammation and enhancing neuronal recovery. However, its potential role in alleviating BCP through the modulation of neuronal ferroptosis remains unexplored. Methods: Ferroptosis was induced by Erastin in SH-SY5Y human neuroblastoma cells. Plasmids were used to overexpress or knock down toll-like receptor (TLR) 2 and cyclooxygenase-2 (COX-2). The effects of argon treatment were evaluated in SH-SY5Y cells in which TLR2 and COX-2 expression was manipulated using viability assays, oxidative stress markers (reactive oxygen species (ROS), malondialdehyde (MDA), and glutathione (GSH)), and ferroptosis-related proteins (acyl-CoA synthetase long-chain family member 4 (ACSL4), glutathione peroxidase 4 (GPX4), and solute carrier family 7 member 11 (SLC7A11)). In vivo, a murine BCP model was developed by injecting Lewis lung carcinoma cells into the femoral cavity. Pain behaviors were analyzed, and spinal cord ferroptosis features were evaluated using histology, immunofluorescence, and transmission electron microscopy (TEM). Results: In vitro experiments showed that argon treatment restored SH-SY5Y cell viability after Erastin exposure, suppressed ROS and MDA production, and boosted GSH levels. It also downregulated ACSL4 and upregulated GPX4 and SLC7A11. In vivo, argon improved pain behaviors, reduced tumor burden, preserved neuronal integrity, and mitigated ferroptosis-induced damage to the spinal cords of BCP model mice. Argon also significantly suppressed TLR2 and COX-2 expression, disrupting the ferroptosis and inflammation cascades. However, overexpression of TLR2 or COX-2 reversed these protective effects, confirming the pivotal role of the TLR2-COX-2 axis in neuronal ferroptosis and pain modulation. Conclusion: These findings demonstrate that argon effectively mitigates neuronal ferroptosis and alleviates BCP by downregulating the TLR2-COX-2 pathway, highlighting its therapeutic potential for conditions involving ferroptosis, such as cancer-related pain and neurodegenerative diseases.
- 25 September 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (9) , 43761
Open AccessArgon Alleviates Bone Cancer Pain by Mitigating Neuronal Ferroptosis via the TLR2-COX-2 Pathway
Background: Bone cancer pain (BCP) related neuronal damage is associated with ferroptosis, a regulated cell death dependent on iron. The noble gas argon is known to have neuroprotective effects, reducing neuroinflammation and enhancing neuronal recovery. However, its potential role in alleviating BCP through the modulation of neuronal ferroptosis remains unexplored. Methods: Ferroptosis was induced by Erastin in SH-SY5Y human neuroblastoma cells. Plasmids were used to overexpress or knock down toll-like receptor (TLR) 2 and cyclooxygenase-2 (COX-2). The effects of argon treatment were evaluated in SH-SY5Y cells in which TLR2 and COX-2 expression was manipulated using viability assays, oxidative stress markers (reactive oxygen species (ROS), malondialdehyde (MDA), and glutathione (GSH)), and ferroptosis-related proteins (acyl-CoA synthetase long-chain family member 4 (ACSL4), glutathione peroxidase 4 (GPX4), and solute carrier family 7 member 11 (SLC7A11)). In vivo, a murine BCP model was developed by injecting Lewis lung carcinoma cells into the femoral cavity. Pain behaviors were analyzed, and spinal cord ferroptosis features were evaluated using histology, immunofluorescence, and transmission electron microscopy (TEM). Results: In vitro experiments showed that argon treatment restored SH-SY5Y cell viability after Erastin exposure, suppressed ROS and MDA production, and boosted GSH levels. It also downregulated ACSL4 and upregulated GPX4 and SLC7A11. In vivo, argon improved pain behaviors, reduced tumor burden, preserved neuronal integrity, and mitigated ferroptosis-induced damage to the spinal cords of BCP model mice. Argon also significantly suppressed TLR2 and COX-2 expression, disrupting the ferroptosis and inflammation cascades. However, overexpression of TLR2 or COX-2 reversed these protective effects, confirming the pivotal role of the TLR2-COX-2 axis in neuronal ferroptosis and pain modulation. Conclusion: These findings demonstrate that argon effectively mitigates neuronal ferroptosis and alleviates BCP by downregulating the TLR2-COX-2 pathway, highlighting its therapeutic potential for conditions involving ferroptosis, such as cancer-related pain and neurodegenerative diseases.
- Open Access
- 2 September 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (9) , e70827
From Tradition to Innovation: Acupuncture Therapies Targeting Ferroptosis in Neurological Disorders
Introduction: Age‐related neurodegenerative diseases (NDDs) and stroke represent significant public health challenges due to their high morbidity, mortality, and associated cognitive decline. Current therapeutic strategies often fall short in addressing the complex underlying pathological mechanisms, underscoring the urgent need for innovative treatment approaches. Ferroptosis, an iron‐dependent form of regulated cell death driven by lipid peroxidation, has emerged as a critical factor contributing to neuronal damage in NDDs and stroke. Methods: To explore how acupuncture‐related therapies may modulate ferroptosis and contribute to neuroprotection, we conducted a comprehensive narrative review. A systematic search was performed in PubMed using targeted keywords including “ferroptosis,” “interventions” (such as acupuncture, electroacupuncture, and moxibustion), and “diseases” (including age‐related neurodegenerative diseases and stroke). The search was restricted to articles published before April 2025 with full‐text availability in English. Results: This review consolidates recent findings on the potential of acupuncture‐related therapies to target ferroptosis in NDDs and stroke. Traditional acupuncture, electroacupuncture (EA), and moxibustion have shown promising neuroprotective effects through multiple mechanisms. Emerging evidence suggests that these interventions can regulate ferroptosis by modulating key molecular pathways involved in iron metabolism, lipid peroxidation, and oxidative stress. These actions are thought to alleviate synaptic dysfunction and slow cognitive decline—processes where ferroptosis plays a central role. Such insights enhance our understanding of how traditional Chinese medicine could influence cognitive outcomes in age‐related NDDs and stroke. Conclusion: Understanding the role of ferroptosis in NDDs and stroke is essential for developing novel therapeutics. Based on current findings, this review proposes future research directions aimed at integrating acupuncture into modern neurotherapeutic frameworks. Combining traditional medicine with contemporary medical approaches offers new opportunities for promoting brain health and improving patient outcomes.
- 2 September 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (9) , e70827
Open AccessFrom Tradition to Innovation: Acupuncture Therapies Targeting Ferroptosis in Neurological Disorders
Introduction: Age‐related neurodegenerative diseases (NDDs) and stroke represent significant public health challenges due to their high morbidity, mortality, and associated cognitive decline. Current therapeutic strategies often fall short in addressing the complex underlying pathological mechanisms, underscoring the urgent need for innovative treatment approaches. Ferroptosis, an iron‐dependent form of regulated cell death driven by lipid peroxidation, has emerged as a critical factor contributing to neuronal damage in NDDs and stroke. Methods: To explore how acupuncture‐related therapies may modulate ferroptosis and contribute to neuroprotection, we conducted a comprehensive narrative review. A systematic search was performed in PubMed using targeted keywords including “ferroptosis,” “interventions” (such as acupuncture, electroacupuncture, and moxibustion), and “diseases” (including age‐related neurodegenerative diseases and stroke). The search was restricted to articles published before April 2025 with full‐text availability in English. Results: This review consolidates recent findings on the potential of acupuncture‐related therapies to target ferroptosis in NDDs and stroke. Traditional acupuncture, electroacupuncture (EA), and moxibustion have shown promising neuroprotective effects through multiple mechanisms. Emerging evidence suggests that these interventions can regulate ferroptosis by modulating key molecular pathways involved in iron metabolism, lipid peroxidation, and oxidative stress. These actions are thought to alleviate synaptic dysfunction and slow cognitive decline—processes where ferroptosis plays a central role. Such insights enhance our understanding of how traditional Chinese medicine could influence cognitive outcomes in age‐related NDDs and stroke. Conclusion: Understanding the role of ferroptosis in NDDs and stroke is essential for developing novel therapeutics. Based on current findings, this review proposes future research directions aimed at integrating acupuncture into modern neurotherapeutic frameworks. Combining traditional medicine with contemporary medical approaches offers new opportunities for promoting brain health and improving patient outcomes.
- Open Access
- 26 July 2021
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 49 (7)
Efficacy of magnesium sulfate as an adjuvant to rocuronium in general anaesthesia: a meta-analysis
Objective: Magnesium sulfate is considered to be an effective adjuvant to rocuronium in general anaesthesia. We conducted a meta-analysis to clarify its efficacy. Methods: We searched the PubMed, Embase, Web of Science, Cochrane Library, WanFang, Chinese Biomedical Literature, and China National Knowledge Infrastructure databases for randomized controlled trials (RCTs) of magnesium sulfate as an adjuvant to rocuronium from the start of the database establishment until May 2020. Results: Eleven RCTs were analysed. The pooled meta-analysis showed that using magnesium sulfate as an adjuvant significantly shortened the onset time and prolonged the clinical duration of neuromuscular blockade by rocuronium compared with the control group without magnesium sulfate. However, there was no significant difference in recovery index of neuromuscular block between the magnesium and control groups. Furthermore, magnesium sulfate significantly increased the rates of excellent and clinically acceptable intubation conditions. Conclusion: Adding magnesium sulfate to rocuronium during general anaesthesia can alter the neuromuscular parameters, including shortening the anaesthesia-onset time and prolonging the clinical duration, without significantly increasing the recovery time. Pretreatment with magnesium sulfate may also improve intubation conditions during general anaesthesia.
- 26 July 2021
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 49 (7)
Open AccessEfficacy of magnesium sulfate as an adjuvant to rocuronium in general anaesthesia: a meta-analysis
Objective: Magnesium sulfate is considered to be an effective adjuvant to rocuronium in general anaesthesia. We conducted a meta-analysis to clarify its efficacy. Methods: We searched the PubMed, Embase, Web of Science, Cochrane Library, WanFang, Chinese Biomedical Literature, and China National Knowledge Infrastructure databases for randomized controlled trials (RCTs) of magnesium sulfate as an adjuvant to rocuronium from the start of the database establishment until May 2020. Results: Eleven RCTs were analysed. The pooled meta-analysis showed that using magnesium sulfate as an adjuvant significantly shortened the onset time and prolonged the clinical duration of neuromuscular blockade by rocuronium compared with the control group without magnesium sulfate. However, there was no significant difference in recovery index of neuromuscular block between the magnesium and control groups. Furthermore, magnesium sulfate significantly increased the rates of excellent and clinically acceptable intubation conditions. Conclusion: Adding magnesium sulfate to rocuronium during general anaesthesia can alter the neuromuscular parameters, including shortening the anaesthesia-onset time and prolonging the clinical duration, without significantly increasing the recovery time. Pretreatment with magnesium sulfate may also improve intubation conditions during general anaesthesia.
- Open Access
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S72-S73
103: Foley plus oxytocin versus oxytocin alone for labor induction ≥ 34 weeks after premature rupture of membranes (PROM): a randomized controlled trial
- 1 January 2017
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 216 (1) , S72-S73
Open Access103: Foley plus oxytocin versus oxytocin alone for labor induction ≥ 34 weeks after premature rupture of membranes (PROM): a randomized controlled trial